Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONET1: Motesanib + Chemo in Advanced NSCLC
NCT00460317Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jul 2007
- Primary completion
- Mar 2011
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of motesanib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Jul 2007; status: terminated.
02
Drugs
motesanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00460317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460317.